^
    Back
    Association details:
    Biomarker:ROS1 D2033N
    Cancer:Non Small Cell Lung Cancer
    Drug:Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Transl Cancer Res
    Title:

    Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors

    Excerpt:
    Putative ROS1 kinase domain crizotinib resistance mutations: D2033N; Drugs with preclinical activity: Lorlatinib, repotrectinib, cabozantinib.
    DOI:
    10.21037/tcr.2018.08.11